On December 7, 2020, Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the closing of its initial public offering, raising $276 million. The shares began trading on The Nasdaq Global Select Market on December 3, 2020, under the symbol “KNTE.” All shares were offered by Kinnate.

A Wilson Sonsini Goodrich & Rosati team, which includes technology transactions attorney Miranda Biven, corporate attorneys Tony Jeffries, Jennifer Knapp, and Lance Brady and patents and innovations attorneys David Clark, Deborah Smith, and Michael Hostetler represented Kinnate Biopharma in the transaction.

For more information, please see Kinnate's press release.